DUBLIN, IRELAND -- (Marketwired) -- 02/23/15 --
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, announced that it has formally opened its new Global Corporate Headquarters in Dublin, located at Connaught House, Burlington Road in Dublin 4. The Company plans to add sixty highly skilled jobs at its headquarter facility over the next three years. The new recruits will fill positions in areas such as Research and Development, Supply Chain and Finance. Members of the Board of Directors and employees of Horizon Pharma were joined by the Taoiseach of Ireland, Mr. Enda Kenny TD and Mr. Martin Shanahan, CEO, IDA Ireland, during the celebration.
"The opening of our new corporate headquarters is a significant milestone in the company's development and Dublin provides a perfect location from which to manage our Company," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We are very impressed with the economic progress Ireland has made in recent years and we believe the outlook for the economy is very positive. Dublin is widely recognized as a leading center for the pharmaceutical industry and has a deep pool of talented young people who can join our team and help us to grow our operations."
An Taoiseach Enda Kenny TD said; "Ireland's reputation as a leading location for business and investment in the life sciences sector is further boosted by this announcement of 60 new highly-skilled jobs for Horizon Pharma in Dublin. Attracting companies like Horizon Pharma to establish and create jobs in Ireland is one of the Government's key missions as we work to secure the recovery and ensure that more people begin to feel the benefits in their daily lives."
Minister for Jobs, Enterprise and Innovation Richard Bruton TD said: "Pharmaceuticals is a key sector which we have targeted as part of our Action Plan for Jobs, and in recent years we have seen a strong jobs performance in this area despite international difficulties. Today's announcement that Horizon Pharma is creating 60 extra high-end jobs for Dublin is another great boost for the city and for the pharma sector in Ireland."
Martin Shanahan, Chief Executive of the IDA said; "In recent years Ireland has built up a cluster of bio pharma companies. This cluster has been further strengthened by Horizon Pharma's decision to locate its new HQ in Dublin and creating sustainable employment across a number of business functions. IDA Ireland looks forward to the further growth of the company in future years."
About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin,
Ireland. For more information, please visit www.horizonpharma.com.
David G. Kelly
Executive Vice President and Managing Director, Ireland
+353 1 772 2100
Ireland Media Contact:
+353 (87) 2417373
Robert F. Carey
Executive Vice President, Chief Business Officer
+353 1 772 2135
U.S. Media Contact:
+1 312 233-1253
Source: Horizon Pharma plc
News Provided by Acquire Media